The American Society for Transplantation and Cellular Therapy ® (ASTCT ®) is pleased to announce David L. Porter, MD, as the Society's president for the 2025-2026 term. A long-standing leader in ...

Cytokine Release Syndrome, or CRS, of Grade 1 or 2 according to ASTCT grading was observed in 34.5% of patients and resolved with standard treatment, the company said. The company added that low ...

Dr. Porter is the Jodi Fisher-Horowitz Professor of Leukemia Care Excellence in the Perelman School of Medicine at the University of Pennsylvania and Abramson Cancer Center, as well as the ...

CHICAGO, ILLINOIS / ACCESS Newswire / February 17, 2025 / The American Society for Transplantation and Cellular Therapy ® (ASTCT ®) is pleased to announce David L. Porter, MD, as the Society's ...

Abstract highlights: An Expanded Access Program (EAP) evaluated outcomes in 29 patients with hematologic malignancies following allo-HCT with omidubicel. Eligible patients ≥12 years of age ...